Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 24

  • 956 clinical trials
  • 393 recruiting
  • 345 conditions
  • 28 countries

Conditions in this area

345 conditions with trials, the busiest first

Breast cancer168Prostate cancer101Ovarian cancer91Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer41Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer18Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+321

Clinical trials in Reproductive system and breast disorders

956 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

956 clinical trials

Prostate cancer metastatic

Recruiting

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Astellas Pharma Global Development Inc.

Breast cancer+3

Recruiting

Study on Oxybutynin and Venlafaxine for Reducing Hot Flashes in Women Undergoing Endocrine Therapy After Breast Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Reinier de Graaf Groep

Prostate cancer

Recruiting

Study on the Safety and Effectiveness of 64Cu-DOTA-AE105 PET Imaging for Patients with Localized, Untreated Prostate Cancer

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:64Cu-Dota-Ae105
  • Sponsor:Curasight A/S

Breast cancer

Recruiting

Study on 68Ga-FAPI-46 for Predicting Treatment Response in Early-Stage High-Risk Triple-Negative Breast Cancer Patients Undergoing Chemo-Immunotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Institut Curie

Lymphoma+6

Recruiting

Study of Tulmimetostat (CPI-0209) for Patients with Advanced Solid Tumors and Lymphomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Novartis Pharma AG

Infertility

Recruiting

Study on the Effectiveness of Vaginal Micronized Progesterone for Infertility in Patients Undergoing Assisted Conception with Frozen Embryo Transfer (AC-FET)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Progesterone
  • Sponsor:Santiago Dexeus Font Fundacio Privada

Endometrial cancer+4

Recruiting

Study of PC14586 for Patients with Advanced Solid Tumors with a Specific TP53 Mutation

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pc14586
  • Sponsor:Pmv Pharmaceuticals Inc.

Breast cancer+1

Recruiting

Study on Detecting Hidden Invasive Breast Cancer in Patients with Ductal Carcinoma In Situ Using [68Ga]FAPI-46 and Gadobutrol

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol
  • Sponsor:Universitaet Muenster

Prostate cancer

Recruiting

Study on Bicalutamide and Drug Combination for Patients with Unfavorable Intermediate/High-Risk Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bicalutamide
  • Sponsor:I.F.O. Istituti Fisioterapici Ospitalieri

Precocious puberty+1

Recruiting

Study on Metformin and Lifestyle Changes for Girls with Early Puberty and Overweight

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Metformin Hydrochloride
  • Sponsor:Region Hovedstaden

Invasive lobular breast carcinoma

Recruiting

Study of Capivasertib and Fulvestrant for Patients with High-Risk Lobular Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:GBG Forschungs GmbH

Peritoneal sarcoma+5

Recruiting

Study on Adjusting Chemotherapy with Carboplatin and Paclitaxel for Patients with Poor Prognostic Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Arcagy Gineco

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab77 clinical trialsLetrozole73 clinical trialsFulvestrant58 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane46 clinical trialsAnastrozole44 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.